摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-4-(4-吗啉基)苯胺 | 347324-26-9

中文名称
3-溴-4-(4-吗啉基)苯胺
中文别名
——
英文名称
3-bromo-4-(4-morpholinyl)-benzenamine
英文别名
3-bromo-4-morpholin-4-ylphenylamine;3-Bromo-4-morpholinoaniline;3-bromo-4-morpholin-4-ylaniline
3-溴-4-(4-吗啉基)苯胺化学式
CAS
347324-26-9
化学式
C10H13BrN2O
mdl
MFCD02081966
分子量
257.13
InChiKey
IWWZCFFYGZRVHR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    410.4±45.0 °C(Predicted)
  • 密度:
    1.501±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    38.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-溴-4-(4-吗啉基)苯胺盐酸 、 sodium azide 、 叔丁基锂 、 sodium nitrite 作用下, 以 四氢呋喃甲醇乙腈正戊烷 为溶剂, 反应 5.84h, 生成
    参考文献:
    名称:
    Fluorogenic Azidofluoresceins for Biological Imaging
    摘要:
    Fluorogenic probes activated by bioorthogonal chemical reactions can enable biomolecule imaging in situations where it is not possible to wash away unbound probe. One challenge for the development of such probes is the a priori identification of structures that will undergo a dramatic fluorescence enhancement by virtue of the chemical transformation. With the aid of density functional theory calculations reported previously by Nagano and co-workers, we identified azidofluorescein derivatives that were predicted to undergo an increase in fluorescence quantum yield upon Cu-catalyzed or Cu-free cycloaddition with linear or cyclic alkynes, respectively. Four derivatives were experimentally verified in model reactions, and one, a 4-azidonaphthylfluorescein analogue, was further shown to label alkyne-functionalized proteins in vitro and glycoproteins on cells with excellent selectivity. The azidofluorescein derivative also enabled cell imaging under no-wash conditions with good signal above background. This work establishes a platform for the rational design of fluorogenic azide probes with spectral properties tailored for biological imaging.
    DOI:
    10.1021/ja308203h
  • 作为产物:
    描述:
    1-acetyl-4-(4-amino-2-methylphenyl)-piperazine4-(2-溴-4-硝基苯基)吗啉 在 Isohexane ethyl acetate 、 3-溴-4-(4-吗啉基)苯胺 作用下, 反应 5.0h, 以was thus obtained the title compound (Intermediate 75) in 24% yield的产率得到3-溴-4-(4-吗啉基)苯胺
    参考文献:
    名称:
    Oxadiazole derivative as DGAT inhibitors
    摘要:
    公式(I)的化合物,以及其盐和前药: 公式(I)其中例如R1是可选取代芳基或杂环芳基; Y是选自直接键和(取代)烷基链等连接基团; R2是可选取代芳基,可选取代环烷基或可选取代杂环基团的化合物已被描述。还描述了制备这些化合物的过程以及它们作为DGAT抑制剂的用途,例如在肥胖症的治疗中。
    公开号:
    US07795283B2
  • 作为试剂:
    描述:
    1-acetyl-4-(4-amino-2-methylphenyl)-piperazine4-(2-溴-4-硝基苯基)吗啉 在 Isohexane ethyl acetate 、 3-溴-4-(4-吗啉基)苯胺 作用下, 反应 5.0h, 以was thus obtained the title compound (Intermediate 75) in 24% yield的产率得到3-溴-4-(4-吗啉基)苯胺
    参考文献:
    名称:
    OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
    摘要:
    公式(I)的化合物、其盐和前药:其中,例如,R1是可选取代芳基或杂环芳基;Y是选自直接键和(取代)烷基链的连接基;R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。本文描述了制备这种化合物的过程,以及它们作为DGAT抑制剂的用途,例如用于治疗肥胖症。
    公开号:
    US20100317653A1
点击查看最新优质反应信息

文献信息

  • [EN] MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS<br/>[FR] COMPOSÉS MACROCYLCIQUES COMME INHIBITEURS D'ALK, DE FAK ET DE JAK2
    申请人:CEPHALON INC
    公开号:WO2012125603A1
    公开(公告)日:2012-09-20
    The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
    本发明提供了式I的化合物或其药用可接受的盐形式,其中R1、R2、R3、R4、R5、A和X如本文所定义,以及其治疗方法和用途。
  • BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS
    申请人:Dierks Christine
    公开号:US20100197659A1
    公开(公告)日:2010-08-05
    The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
    该发明提供了一种调节刺猬信号通路活性的方法。具体来说,该发明提供了一种抑制由于Ptc功能丧失、刺猬功能增强、smoothened功能增强或Gli功能增强等表型引起的异常生长状态的方法,包括将细胞与化合物I式的足够量接触。
  • COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS
    申请人:Gao Wenqi
    公开号:US20090203666A1
    公开(公告)日:2009-08-13
    The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
    本发明提供了一种调节刺猬信号通路活性的方法。具体而言,本发明提供了一种通过接触细胞与化合物I的足够量来抑制由于Ptc功能缺失、刺猬功能增强、平滑蛋白功能增强或Gli功能增强等表型引起的异常生长状态的方法。
  • ALKYNE-ACTIVATED FLUOROGENIC AZIDE COMPOUNDS AND METHODS OF USE THEREOF
    申请人:The Regents of the University of California
    公开号:US20150276752A1
    公开(公告)日:2015-10-01
    The present disclosure provides fluorogenic azide compounds. Also provided are methods of using the subject compounds for labelling a target biomolecule that includes an alkyne. In some embodiments, the method includes contacting the biomolecule with a fluorogenic azide compound, wherein the contacting results in covalent linkage of the compound with the alkyne moiety of the target biomolecule.
    本公开提供了荧光偶氮化物化合物。还提供了使用该化合物标记包含炔基的目标生物分子的方法。在某些实施例中,该方法包括将生物分子与荧光偶氮化物化合物接触,其中接触导致化合物与目标生物分子的炔基部分形成共价键合。
  • Oxadiazole Derivative as Dgat Inhibitors
    申请人:Birch Martin Alan
    公开号:US20080096874A1
    公开(公告)日:2008-04-24
    Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
    式(I)的化合物,以及其盐和前药:其中,例如R1是可选取代芳基或杂环芳基;Y是选择自直接键和(取代)烷基链等的连接基;R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。还描述了制备此类化合物的方法及其作为DGAT抑制剂的用途,例如在肥胖症的治疗中。
查看更多